26th Nov 2013 11:19
LONDON (Alliance News) - BTG PLC rose to the top of the FTSE 250 Tuesday after it announced that it had received approval from the US Food and Drug Administration for its varicose vein treatment Varithena.
The healthcare company will launch the project commercially in the US during the second quarter of 2014.
Shares in BTG were trading up 10.91% at 508.95 pence Tuesday morning.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright © 2013 Alliance News Limited. All Rights Reserved.
Related Shares:
BTG